DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Drozitumab
Drozitumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Activating Death Receptor DR5 As a Therapeutic Strategy for Rhabdomyosarcoma
Tanibirumab (CUI C3490677) Add to Cart
Pancreatic Cancer Stem Cells in Patient Pancreatic Xenografts Are Sensitive to Drozitumab, an Agonistic Antibody Against DR5 Jason W.-L
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
NSCLC Therapeutics in Asia-Pacific Markets to 2019 Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Pre-Activation of the P53 Pathway Through Nutlin-3A Sensitises Sarcomas to Drozitumab Therapy Oncology Reports, 2013; 30(1):471-477
Focus on Approved and In-Clinical-Trial Monoclonal Antibodies
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
(INN) for Biological and Biotechnological Substances
WO 2014/075788 Al 22 May 2014 (22.05.2014) P O P C T
Top View
International Nonproprietary Names for Pharmaceutical Substances (INN)
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
A61K9/51 (2006.01) — with International Search Report (Art
| Hao Hata Kata Tai Mit on a Man Taiwan Ta Material
N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity Against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response
WO 2018/183580 Al 04 October 2018 (04.10.2018) W !P O PCT
Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity Against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Monoclonal Antibodies and Chimeric Antigen Receptor
(12) United States Patent (10) Patent No.: US 9.295,731 B2 Nguyen (45) Date of Patent: Mar
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
The TRAIL Receptor Agonist Drozitumab Targets Basal B Triple Negative Breast Cancer Cells That Express Vimentin and Axl
University of Groningen Targeted Therapy, Molecular Imaging And
Principles of Antibody-Mediated TNF Receptor Activation
Therapeutic Efficacy and Safety of a Human Fusion Construct Targeting the TWEAK Receptor Fn14 and Containing a Modified Granzyme B
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
Ep 3088005 A1
Pre-Activation of the P53 Pathway Through Nutlin-3A Sensitises Sarcomas to Drozitumab Therapy
Timepoint 1 Geting Assembly Complexes (Attacs) for Selectively Activating De¬ Sired Immune Cells in the Tumor Microenvironment
(12) United States Patent (10) Patent No.: US 9,364,567 B2 Vitalis Et Al
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
On the TRAIL to Successful Cancer Therapy? Predicting and Counteracting Resistance Against TRAIL-Based Therapeutics
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al